Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00002046
Other study ID # 014G
Secondary ID 18
Status Completed
Phase N/A
First received November 2, 1999
Last updated June 23, 2005

Study information

Verified date May 1990
Source NIH AIDS Clinical Trials Information Service
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 13 Years and older
Eligibility Inclusion Criteria

Concurrent Treatment:

Allowed:

- Electron beam therapy to an area of less than 100 cm2.

Patients with the following are excluded:

- Any immediately life-threatening infection or medical condition present at the time of study entry.

- Any active opportunistic or other infection requiring chronic therapy present at the time of study entry.

- Patients with Pneumocystis carinii pneumonia (PCP) may be randomized to study medication following a minimum 7-day course of therapy resulting in stabilization of their disease. Patients with stabilized disease must have fever < 39 degrees C for at least 48 hours; oxygen (on room air)

= or > 60 mm, and arterial / alveolar gradient = or < 30 mm.

- Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.

Seropositive for HIV antibody documented by any federally licensed ELISA.

Patients must have ability to give informed consent and advanced HIV disease defined as:

- History of Pneumocystis carinii pneumonia (PCP) with histologic verification within 4 months of study entry.

OR History of other opportunistic infection included in the CDC surveillance definition of AIDS (stage IV-C-1), diagnosed within 4 months of entry, but not requiring chronic suppressive therapy, and a CD4+ cell count < 200 cells/mm3.

OR AIDS related complex (ARC) only those patients with a CD4+ count < 200 cells/mm3 and documentation of at least two signs or symptoms from the list below. One sign or symptom must be weight loss or candidiasis as described.

- Unexplained weight loss > 10 percent or = or > 15 lbs within the previous 4 months; with low weight at entry.

- History of mucocutaneous oral candidiasis (by culture or potassium hydroxide KOH smear).

- Fever > 38 degrees C, without documented infectious cause present, persisting > 1 month.

- Oral hairy leukoplakia.

- Unexplained night sweats, persisting > 1 month.

- Herpes zoster infection within 3 months of entry.

- Chronic diarrhea of unknown infectious etiology persisting > 1 month after 3 samples have been done eliminating ova, parasites, Cryptosporidia, Mycobacterium avium intracellulare, cytomegalovirus (CMV), and other pathogens associated with diarrheal disease in AIDS patients.

Negative Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagent (RPR) or, if positive and verified by Fluorescent Treponemal Antibody Absorption (FTAABS), documented history of treatment for syphilis. If FTAABS is positive, but treatment history is not available, the patient may be entered 3 or more days following the initiation of appropriate chemotherapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

- Chronic herpes virus infection.

- Fever > 39 degrees C at study entry.

- Known hypersensitivity to lactate and/or gelatin.

- Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.

- Impaired renal function.

- AIDS dementia complex.

Concurrent Medication:

Excluded:

- Drugs which cause significant bone marrow suppression.

- Rifampin or rifampin derivatives.

- Drugs which cause significant nephrotoxicity or hepatotoxicity.

- Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine, didanosine, foscarnet, dextran sulfate, and AL-721.

- Acyclovir therapy of more than 21 days duration.

Concurrent Treatment:

Excluded:

- Radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2).

- Experimental therapy.

- Cytolytic chemotherapy.

Prior Medication:

Excluded:

- Acyclovir therapy of more than 21 days duration.

- Zidovudine (AZT).

- Excluded within 2 weeks of study entry:

- Drugs which cause significant bone marrow suppression.

- Rifampin or rifampin derivatives.

- Drugs which cause significant nephrotoxicity or hepatotoxicity.

- Immunomodulating agents, including pharmacologic doses of steroids for > 10 days.

- Excluded within 4 weeks of study entry:

- Interferon.

- Isoprinosine.

- IL-2.

- Excluded within 8 weeks of study entry:

- Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine, didanosine, foscarnet, dextran sulfate, and AL-721.

Prior Treatment:

Excluded:

- Radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2).

- Experimental therapy.

- Cytolytic chemotherapy.

Active drug or alcohol abuse.

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Zidovudine


Locations

Country Name City State
United States Univ of New Mexico Hlth Sciences Ctr / Dept of Med Albuquerque New Mexico
United States Johns Hopkins Hosp Baltimore Maryland
United States Cook County Hosp Chicago Illinois
United States Northwestern Univ Med School Chicago Illinois
United States Rush Presbyterian - Saint Luke's Med Ctr Chicago Illinois
United States Univ TX Galveston Med Branch Galveston Texas
United States Baylor College of Medicine Houston Texas
United States Univ of Missouri at Kansas City School of Medicine Kansas City Missouri
United States Northshore Hosp / Cornell Univ Manhasset New York
United States Univ of Pennsylvania / HIV Clinic Philadelphia Pennsylvania
United States Univ of Arizona / Health Science Ctr Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Glaxo Wellcome

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2